A sharp biotech satire about habit culture, Big Food, Big Pharma, and the quiet corporate loop that profits when nothing changes. Lives eats chips. Scienz connects the dots. The system does the rest.

Recent exits by Novo Nordisk, Takeda, and Galapagos reveal a truth biotech can’t ignore: the science of cell therapy is ahead of the systems built to deliver it. Scaling life itself demands more than investment — it demands reinvention.

“Fail fast” was meant to drive smarter decisions. Instead, it became a slogan that excuses repetition. In biotech, failure teaches only when it’s deliberate. Everything else is just theater.

Biotech headlines show billion-euro deals, but real success often means surviving another quarter. In this Scienz & Lives story, optimism meets the invoice.

Science fills the program, but networking shapes the outcome. In this Scienz & Lives story, the spotlight shifts from the podium to the people behind the progress.

How many therapies never reach patients because capital flows to the best story instead?

What’s the worst that could happen if you skip ethics approval? Let’s say someone’s about to learn what “violation report” means.

When your fake deck gets more investor interest than your real science, you start to wonder which one the industry actually values.